Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus

BACKGROUND: SGLT‐2 (sodium glucose transporter‐2) inhibitors and GLP‐1RAs (glucagon‐like peptide‐1 receptor agonists) effectively lowered cardiovascular risk in large clinical trials for patients with type 2 diabetes mellitus at high risk for these complications, and have been recommended by guideli...

Descripción completa

Detalles Bibliográficos
Autores principales: Nargesi, Arash A., Jeyashanmugaraja, Gini P., Desai, Nihar, Lipska, Kasia, Krumholz, Harlan, Khera, Rohan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403287/
https://www.ncbi.nlm.nih.gov/pubmed/33998258
http://dx.doi.org/10.1161/JAHA.121.021084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403287/
https://www.ncbi.nlm.nih.gov/pubmed/33998258
http://dx.doi.org/10.1161/JAHA.121.021084

Ejemplares similares